These results show a sustained benefit in event-free survival from trastuzumab-containing neoadjuvant therapy followed by adjuvant trastuzumab in patients with locally advanced or inflammatory breast cancer , and provide new insight into the association between pathological complete remission and long-term outcomes in HER2-positive disease .